One of the most important and least discussed aspects of microdosing is how psychedelics interact with other medications. Many people who explore microdosing are already taking prescription medications—often for the same conditions they hope microdosing might help with. Understanding these interactions isn't optional; it's essential.
Dangerous Combinations
MAOIs and psychedelics. Monoamine oxidase inhibitors are the most dangerous class to combine with psychedelics. MAOIs prevent the breakdown of serotonin, and psychedelics increase serotonin activity. Together, they can cause serotonin syndrome—a potentially fatal condition marked by agitation, high fever, rapid heart rate, and in severe cases, seizures and organ failure.
Common MAOIs include phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), and selegiline (Emsam), as well as the antibiotic linezolid (Zyvox). If you take any of these, do not microdose.
Lithium. The combination of lithium with psychedelics has been linked to seizures and severe adverse reactions. This is well-documented enough in case reports that it should be treated as an absolute contraindication. There is no safe way to combine lithium with psilocybin or LSD. For a broader overview of absolute contraindications, see who should not microdose.
Reduced Effectiveness
SSRIs (selective serotonin reuptake inhibitors). Medications like sertraline (Zoloft), fluoxetine (Prozac), paroxetine (Paxil), citalopram (Celexa), and escitalopram (Lexapro) work on the same serotonin system that psychedelics target. Most people on SSRIs report significantly reduced effects from microdosing—sometimes feeling nothing at all.
This happens because SSRIs alter serotonin receptor density and sensitivity over time. The receptors that psychedelics primarily activate become partially downregulated, blunting the response.
Some people consider reducing or stopping their SSRI to microdose. This is a decision that should only be made with medical supervision. Stopping SSRIs abruptly can cause withdrawal symptoms—sometimes severe—and the underlying condition the medication treats may return.
SNRIs (serotonin-norepinephrine reuptake inhibitors). Medications like venlafaxine (Effexor) and duloxetine (Cymbalta) have similar effects on microdosing response as SSRIs, with the added complication of norepinephrine involvement. The same cautions about discontinuation apply.
Complex Interactions
Antipsychotics. Medications like risperidone, olanzapine, quetiapine, and aripiprazole block the very receptors that psychedelics activate. They effectively cancel out microdosing effects. More importantly, if you're prescribed antipsychotics, that's a strong signal that psychedelics may not be appropriate for your situation.
Tramadol. This pain medication has serotonergic properties and carries a risk of serotonin syndrome when combined with psychedelics. It also lowers the seizure threshold, adding another layer of risk.
Stimulant medications. ADHD medications like methylphenidate (Ritalin) and amphetamine-based drugs (Adderall) interact with microdosing in complex ways. Reports are mixed—some people find the combination manageable, others experience increased anxiety, cardiovascular effects, or unpredictable mood shifts. If you take stimulants for ADHD, start with extreme caution and consider whether the potential benefits justify the added uncertainty. Our article on microdosing and ADHD explores this topic in more depth.
Cannabis. While not a prescription medication for most users, cannabis is commonly used alongside microdosing. It can amplify psychedelic effects unpredictably and may mask or distort the subtle signals that microdosing provides. Many experienced microdosers recommend keeping them separate, at least initially.
Blood pressure medications. Some psychedelics temporarily raise blood pressure and heart rate. See our heart health guide for more on cardiovascular considerations. If you take medication for hypertension, monitor your blood pressure more closely during a microdosing protocol and discuss this with your prescriber if possible.
The Conversation Problem
Perhaps the biggest challenge with medication interactions is the conversation itself. Many people don't feel comfortable telling their prescribing doctor that they're microdosing. And many doctors, even well-meaning ones, lack specific knowledge about psychedelic interactions.
This creates a dangerous information gap. If your doctor doesn't know you're microdosing, they can't account for potential interactions when adjusting your medications. And if you're relying solely on online forums for interaction information, you may be getting incomplete or inaccurate guidance.
The ideal scenario is honest communication with a knowledgeable healthcare provider. Where that's not possible, harm reduction organizations and psychedelic-informed therapists can sometimes bridge the gap.